Transforming depression with an innovative neurobehavioral assay to assess potentially novel antidepressants

Learn about Inscopix's latest contract research services (CRO) for pharmaceutical companies and biotech. Dr. Jonathan Nassi demonstrates the cutting-edge capabilities of the Inscopix Discovery Lab, using advanced in vivo miniscope imaging integrated with behavioral analysis. This innovative method supports pharmaceutical preclinical programs by providing a unique way to evaluate new compounds and understand the effects of drugs on brain function during active behavior. Additionally, he highlights an antidepressant profiling and reference library developed in collaboration with pharma. One such collaboration, and the resulting data, is presented in this webinar.

Dr. Benjamin Siemsen of Supernus Pharmaceuticals, Inc. unveils the newest findings from a project conducted through the Inscopix Discovery Lab, in a presentation titled,

NV-5138 screening through Inscopix neurobehavioral assay: Comparison with ketamine and rapastinel

The need for rapid onset time coupled with improved efficacy has ushered in a wave of innovations in antidepressant pharmacotherapeutics. These so-called rapid-acting antidepressants (RAADs) are thought to engage the brain’s neuroplasticity mechanisms in key brain regions implicated in depression etiology, such as the prefrontal cortex (PFC). NV-5138 is a Phase 2 drug candidate with potential RAAD effects that was recently screened through the Inscopix neurobehavioral assay. Relative to ketamine and rapastinel, NV-5138 displayed a unique neurobehavioral signature that will be discussed in detail during this webinar.

Find out more about the technology featured in this webinar or our other solutions for Miniscope Imaging: